Table 4.
SNP | n | Hypertension |
Univariate exact logistic regression |
Multivariable exact logistic regressiona |
|||
---|---|---|---|---|---|---|---|
0–1 | 2–3 | Exact odds ratio (95% CI) | P valueb | Exact odds ratio (95% CI) | P valueb | ||
Validation cohort (FIRE-3 bevacizumab arm) | |||||||
ATG13rs13448 | 0.85 | 0.85 | |||||
T/T | 74 | 62 (84%) | 12 (16%) | 1 (Reference) | 1 (Reference) | ||
Any C | 145 | 119 (82%) | 26 (18%) | 1.13 (0.51, 2.63) | 1.13 (0.50, 2.67) | ||
FIP200rs1129660 | 0.077 | 0.072 | |||||
A/A | 167 | 134 (80%) | 33 (20%) | 1 (Reference) | 1 (Reference) | ||
Any G | 63 | 57 (91%) | 6 (9%) | 0.43 (0.14, 1.11) | 0.41 (0.13, 1.07) | ||
Control cohort (FIRE-3 cetuximab arm) | |||||||
FIP200rs1129660 | 0.60 | 0.60 | |||||
A/A | 146 | 133 (91%) | 13 (9%) | 1 (Reference) | 1 (Reference) | ||
Any G | 58 | 51 (88%) | 7 (12%) | 1.40 (0.45, 4.04) | 1.38 (0.44, 3.97) |
Multivariable model was adjusted for sex (female versus male), age (<65 versus ≤65) and BMI (<25 versus ≤25).
P value was based on exact conditional scores test from exact logistic regression.